Compare Stella Pharma Corp. with Similar Stocks
Dashboard
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
Poor long term growth as Operating profit has grown by an annual rate -234.76% of over the last 5 years
Risky - Negative EBITDA
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 8,066 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.73
-6.21%
2.78
Total Returns (Price + Dividend) 
Stella Pharma Corp. for the last several years.
Risk Adjusted Returns v/s 
News

Stella Pharma Corp. Hits Day Low at JPY 266 Amid Price Pressure
Stella Pharma Corp. has faced notable volatility, with a significant stock decline today and a substantial drop over the past week and month. Year-to-date, the stock has decreased sharply, reflecting ongoing financial challenges, including negative returns and operating profit growth. The company’s performance lags behind the broader market.
Read full news article Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is -86.93% vs 734.71% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -167.31% vs 321.93% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
YoY Growth in year ended Mar 2025 is 256.62% vs 17.63% in Mar 2024
YoY Growth in year ended Mar 2025 is 81.56% vs 1.94% in Mar 2024






